Protein S100A8/A9: A Potential New Biomarker for Pancreatic Diseases

• Main Authors: El Gammal AT (Author), Sturm JH (Author), Pinnschmidt HO (Author), Hofmann BT (Author), Bellon E (Author), et al (Author)
• Format: Book
• Published: International Journal of Clinical Endocrinology and Metabolism - Peertechz Publications, 2017-09-19.
• Subjects: Research Article
• Online Access: Connect to this object online.

Summary

<p><strong>Objectives:</strong> S100A8/A9  expression  has  been  linked  to  carcinogenesis  and  inflammation.We hypothesized  that  S100A8/A9  protein  serum  levels  are  a  useful  stratification  marker  for  patients  with pancreatic  ductal  adenocarcinoma  (PDAC),  intraductal  papillary  mucinous  neoplasm  (IPMN)  or  chronic pancreatitis (CP). </p><p><strong>Methods:</strong> S100A8/A9 serum levels were analysed in PDAC, CP and IPMN patients and compared to S100A8/A9 healthy donor controls (HD) using ELISA. S100A8/A9 levels and clinical data were statistically analysed. </p><p><strong>Results:</strong> Out  of134  patients  included,  84  were  diagnosed  with  PDAC  (46%),  30  patients with  IPMN  (16%) and 20 patients with CP (11%), 50 patients were HD (27%). When compared to HD (343.3 ng/ml), S100A8/A9 serum concentration was elevated in PDAC (402.0 ng/ml, p = 0.001) and CP patients (426.51 ng/ml p < 0.001). Also, S100A8/A9 levels were elevated in PDAC compared to IPMN group (369.0 ng/ml p  =  0.026)  and  in  CP  compared  to  IPMN  group  (p  =  0.001).  A  multivariate  model  including  age,  gender, leukocyte levels, C-reactive protein (CrP), S100A8/A9 and CA 19-9 concentrations reported a diagnostic sensitivity of 74.8%.</p><p><strong>Conclusion:</strong> S100A8/A9 serum levels are increased in patients with PDAC, CP, and IPM might be useful to distinguish malignant and inflammatory diseases from normal and non-malignant pathological conditions.<br></p><br>

DOI

10.17352/ijcem.000025